Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ViaCyte
Biotech
Vertex cuts ties to CRISPR’s type 1 diabetes stem cell therapy
Vertex has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte.
Nick Paul Taylor
Jan 8, 2024 9:16am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
Vertex's T1D cell therapy spurs insulin production in 6 patients
Jun 26, 2023 10:28am
Vertex buys ViaCyte for $320M, clearing out T1D competition
Jul 11, 2022 11:45am
AltruBio snags new CMO with pivot to immunology—Chutes & Ladders
Sep 17, 2021 9:30am
ViaCyte staffs up CSO role to drive diabetes treatments
Sep 13, 2021 1:00pm
